Selected article for: "group time point and time point"
Author: Kim, Chang-Keun; Callaway, Zak; Park, Jin-Sung; Nishimori, Hisashi; Ogino, Tikatoshi; Nagao, Mizuho; Fujisawa, Takao
Title: Montelukast Reduces Serum Levels of Eosinophil-Derived Neurotoxin in Preschool Asthma
  • Document date: 2018_8_30
    • ID: uzge50xu_23
    Snippet: Laboratory data at entry can be found in Table 2 . HDM-IgE and send levels in the OBS group were significantly lower when compared to the other 2 groups. This was expected because to be included in the OBS group a patient had to have a sEDN level < 53 ng/mL, no sensitivity to HDM or both. ACD ACD increased significantly in each group (P < 0.000) from the beginning of the study (0 week) to the end of the study (12 weeks). However, when comparing A.....
    Document: Laboratory data at entry can be found in Table 2 . HDM-IgE and send levels in the OBS group were significantly lower when compared to the other 2 groups. This was expected because to be included in the OBS group a patient had to have a sEDN level < 53 ng/mL, no sensitivity to HDM or both. ACD ACD increased significantly in each group (P < 0.000) from the beginning of the study (0 week) to the end of the study (12 weeks). However, when comparing ACD of each group at each time point, there were no significant differences (Fig. 3) BIS, budesonide inhalation suspension; MONT, eligible and receiving montelukast; OBS, not eligible and receiving montelukast. *Age in OBS group significantly lower (P < 0.05); † % Atopic dermatitis significantly less (P < 0.05).

    Search related documents:
    Co phrase search for related documents
    • atopic dermatitis and significant difference: 1, 2, 3, 4, 5
    • atopic dermatitis and significantly atopic dermatitis: 1, 2, 3, 4, 5
    • atopic dermatitis and time point: 1
    • budesonide inhalation suspension and inhalation suspension: 1, 2
    • budesonide inhalation suspension and montelukast receive: 1, 2
    • budesonide inhalation suspension and OBS group: 1, 2
    • budesonide inhalation suspension and sEDN level: 1
    • budesonide inhalation suspension bis and inhalation suspension: 1, 2
    • budesonide inhalation suspension bis and montelukast receive: 1, 2
    • budesonide inhalation suspension bis and OBS group: 1, 2
    • budesonide inhalation suspension bis and sEDN level: 1
    • HDM sensitivity and OBS group: 1, 2
    • inhalation suspension and montelukast receive: 1, 2
    • inhalation suspension and OBS group: 1, 2
    • inhalation suspension and sEDN level: 1
    • montelukast receive and OBS group: 1, 2
    • montelukast receive and sEDN level: 1
    • OBS group and sEDN level: 1
    • significant difference and time point: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25